Atezolizumab Combined With Platinum-based Chemotherapy as Neoadjuvant Therapy for Patients With Resectable Stage II-IIIB
This study aimed to evaluate the efficacy, safety, tolerability, feasibility of surgery, and incidence of preoperative and postoperative complications of atezolizumab in combination with platinum-based chemotherapy with resectable stage II-IIIB non-small cell lung cancer.
Non Small Cell Lung Cancer
DRUG: Atezolizumab
MPR Rate, Major pathological remissions, 1.5 year|MRD negative Rate, Minimal residual disease rate, 1.5 year
pCR, Defined as the proportion of subjects with complete remission (CR), partial remission (PR) and stable disease (SD) to the total subjects, 1.5 year|DFS, disease-free survival, 1.5 year|EFS, event-free survival, 1.5 year|ORR, Overal response rat, 1.5 year|OS, Overall survival time, 1.5 year
This study aimed to evaluate the efficacy, safety, tolerability, feasibility of surgery, and incidence of preoperative and postoperative complications of atezolizumab in combination with platinum-based chemotherapy with resectable stage II-IIIB non-small cell lung cancer.